Onco-Summaries: Daily Oncology Updates at a Glance

02/06/2026

---

• FDA accepts NDA and grants priority review to Roche’s giredestrant for early-stage ER+, HER2- breast cancer

• Candel’s CAN‑2409 Phase 3 in localized prostate cancer shows significant DFS benefit with favorable safety, supporting BLA filing in Q4 2026

  
  

• Cycle Pharma secures FDA approval for CAVHANZA™, the first nilotinib ODT eliminating PPI/H₂RA timing restrictions to broaden Ph+ CML treatment flexibility

---

FDA accepts NDA and grants priority review to Roche’s giredestrant for early-stage ER+, HER2- breast cancer (Ref)

The FDA has accepted Roche’s New Drug Application for giredestrant, an oral selective oestrogen receptor degrader (SERD), under priority review for ER-positive, HER2-negative stage I–III breast cancer

The FDA has set a Prescription Drug User Fee Act date of 30 November 2026

The filing acceptance is based on the Phase 3 lidERA trial results

• Giredestrant reduced the risk of invasive disease recurrence or death by 30% vs. standard endocrine therapy (HR=0.70, p=0.0014)

• At 3 years, 92.4% of patients on giredestrant were disease-free vs. 89.6% on standard therapy

• Benefit was consistent across subgroups; overall survival data are immature but trending positive

Return to Top

Candel’s CAN‑2409 Phase 3 in localized prostate cancer shows significant DFS benefit with favorable safety, supporting BLA filing in Q4 2026 (Ref)

Pivotal Phase 3 data on aglatimagene besadenovec (CAN‑2409) in localized prostate cancer published in The Lancet Oncology

Efficacy Results:

• 30% improvement in disease‑free survival (DFS) vs. placebo (HR 0.70; p=0.016).

• 38% improvement in prostate cancer‑specific DFS (HR 0.62; p=0.0046).

• Pathological complete response: 80% negative biopsies in aglatimagene arm vs. 63% in placebo (p=0.0018).

• Extended follow‑up showed 39% improvement in prostate cancer‑specific DFS at 58 months

Data will support a Biologics License Application (BLA) submission in Q4 2026.

• FDA has granted Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations for localized prostate cancer, plus Fast Track in NSCLC and Orphan Drug in PDAC

Return to Top

Cycle Pharma secures FDA approval for CAVHANZA™, the first nilotinib ODT eliminating PPI/H₂RA timing restrictions to broaden Ph+ CML treatment flexibility (Ref)

FDA approved Cycle Pharmaceuticals' CAVHANZA™ (nilotinib) orally disintegrating tablets for Ph+ chronic myeloid leukemia (CML) patients in chronic and accelerated phases, including those resistant/intolerant to prior therapy

First nilotinib formulation designed to maintain bioavailability even with acid-reducing agents (PPIs/H₂RAs), eliminating timing restrictions

Demonstrated no food effect in trials; can be taken regardless of meals, reducing patient burden

Return to Top